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dramatically and CPK levels were normal in spite of the fact that 
he .had resumed taking lovastatin. 
With the patient’s consent we challenged him with diltiazem; 
again, myopathy and very high CPK levels developed. When dil- 
tiazem was discontinued the patient’s symptoms cleared rapidly; 
elevated CPK levels returned to normal over the ensuing 5 days. 
Results of the challenge, dechallenge, and rechallenge attest that 
the diltiazem was the culprit in inducing the myopathy. The man- 
ufacturer has received reports of diltiazem-induced-myopathy, 
and it is listed as a possible side effect in their package insert. 
Nevertheless, to my knowledge this article appears to be the first 
published about a patient with this drug-induced myopathy. In 
view of this clinical observation, I suggest that diltiazem therapy 
be added to the list of drugs considered to be potential causes of 
a drug-induced my0pathy.i 
Saeed Ahmad, MD 
West Virginia University 
1000 Brookside Dr. 
Fairmont, WV 26554 
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4/8/49960 
ARTERIAL THROMBOSIS IN 
THROMBOCYTHEMIA 
To the Editor: 
Erythromelalgia is a typical thrombotic manifestation of pril 
mary thrombocythemia or thrombocythemia in association with 
polycythemia Vera, occurring at platelet counts in excess of 
400 X10g/L.1-3 The painful erythromelalgic burning and red con- 
gestion of toes, fingers, or soles of the feet frequently progress to 
painful ischemic acrocyanosis and peripheral gangrene if left un- 
treated. The specific histopathology of erythromelalgic lesions 
shows a thrombotic occlusion of the acral a.rterial microvasculature 
without evidence of preexisting vascular disease.l, 2 From 1978 to 
the present, we documented 59 consecutive cases of primary 
thrombocythemia and 26 cases of thrombocythemia associated 
with polycythemia Vera. The specific manifestations in 55 symp- 
tomatic patients were erythromelalgia in 43, cerebrovascular dis- 
ease in 23, and coronary artery disease in nine patients. To exclude 
polycythemia vera as a contributory,factor in arterial vascular 
disease, the presenting coronary, neurologic, and visual ischemic 
symptoms in 22 patients with primary thrombocythemia were 
studied. 
Coronary events in nine cases were myocardial infarction in four 
and unstable angina pectoris in five. Cardiac catherization was 
performed in eight patients. Two patients with myocardial infarc- 
tion had normal coronary arteries. A third patient with myocardial 
infarction had a totally occluded coronary artery but no other signs 
of atherosclerosis in the remaining coronary and peripheral arter- 
ies. The five patients with unstable angina pectoris had coronary 
disease (one-vessel disease in two and two-vessel disease in three) 
and underwent coronary bypass surgery. Nineteen patients pre- 
sented neurologic or visual ischemic symptoms. Eleven patients 
had focal symptoms: transient monocular blindness in three, 
transient monoparesis or hemiparesis in six patients, and both in 
one; migraine in one, and partial stroke in one. Nonfocal symptoms 
occurred in 14 patients: transient postural instability in 13, dysar- 
thria in eight,.and scintillating scotomas in five. The transient fo- 
cal and nonfocal neurologic and visual symptoms all had a sudden 
onset, occurred in a progression rather than all at once, lasted for 
a few seconds to several minutes, and were usually associated with 
or followed by a dull or pulsatile headache. This clinical presen- 
tation is very atypical of transient ischemic attacks caused by 
atherosclerosis, but the striking similarity with migraine supports 
the crucial role of platelets in the pathogenesis of ischemic circu- 
lation disturbances in primary thrombocythemia. Only four of the 
patients with primary thrombocythemia had one or more of the 
known risk factors for vascular disease: hypertension, hypercho- 
lesterolemia, diabetes, or a family history of arterial thrombosis. 
Smoking was the single risk factor in four cases. The peripheral 
arterial pulses were normal in all patients, indicating absence of 
clinical relevant atherosclerosis. However, an arterial thrombotic 
tendency was present in 12 patients, in whom erythromelalgia 
caused by platelet-mediated thrombosis1-3 preceded or followed 
the coronary artery disease or the transient cerebral or ocular 
ischemic attacks. 
Time lapses of thrombotic or iachemic events ranged from 1 to 
7 years, Recurrent thrombotic or ischemic events of the coronary 
or cerebral circulation were recorded in ,five patients while they 
were receiving adequate warfarin treatment. During continuous 
treatment with low doses of aspirin (250 to 500 mg/day) for 1 to 
9 years, there was no recurrence of vascular events in 14 patients 
with primary thrombocythemia at platelet counts of 520 to 
1380 X log/L. Eleven patients maintained remissions of primary 
thrombocythemia (platelet counts less than 350 x log/L) for 3 to 
7 years after treatment with busulfan and remained asymptom- 
atic. It is concluded that thrombocythemia is a main risk factor for 
arterial thrombosis43 5 Moreover, our observations indicate that in 
thrombocythemia platelets are primarily involved in the etiology 
of the thrombotic occlusions of the acral arterial microvasculature 
as well as the coronary and cerebral circulation. In contrast, 
thrombotic events are rare or not observed in patients with reac- 
tive thrombocytosis. We therefore prospectively performed ki- 
netic studies of 51Cr-labeled autologous platelets in 10 patients 
with thrombocythemia complicated by erythromelalgia (E+), in 10 
asymptomatic patients with thrombocythemia (E-), and in 10 
control subjects with reactive thrombocytosis (RT).6 The mean 
survival (MS) of platelets in the E+ group was significantly 
decreased compared with both the E- and RT groups (p < O.OOl), 
indicating platelet consumption in symptomatic patients with 
thrombocythemia and erythromelalgia. Continued treatment with 
500 mg of aspirin per day normalized the MS of E+ patients 
(p < 0.001) by suppressing platelet consumption, resulting in 
complete relief of erythromelalgic distress and restoration of the 
ischemic and thrombotic circulation disturbances. These findings 
indicate that an intrinsic platelet defect may underly the observed 
thrombotic predisposition in thrombocythemia. 
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CHAGAS’ DISEASE IN NORTH AMERICA 
To the Editor: 
American trypanosomiasis (AT) or Chagas’ disease is a zoonosis 
indigenous and still limited to America, caused by the hemoflagel- 
late Trypanosoma cruzi, which infests the blood and tissues of 
mammalian hosts. It causes a chronic heart disease that still has 
no effective treatment. A high prevalence of AT has been reported 
in South America, where 24,000,OOO people are infected. The dis- 
ease occurs from latitude 36O North to 36” South, that is from Ti- 
juana at the U.S.-Mexican border to Bariloche in Argentina, spar- 
ing only the high mountains and the Amazonian basin:l, 2 Although 
Mexican cases have been described since 1940 as parasitemic dis- 
ease and heart involvement has been recognized several times 
since 1965, for many years it was thought that AT was a rare con- 
dition in North America, including Mexico. A general concept was 
that North American strains of T. cruzi were less pathogenic than 
South American ones, and no information in regard to the presence 
of chronic chagasic cardiopathy existed in Mexico until the late 
197os.a-s 
To ascertain the incidence of immunoglobulin G (IgG) antibod- 
ies to T. cruzi in people admitted to our Institute with dilated car- 
diomyopathy, a diagnosis that represents 2.5% of all yearly 
admissions and 2.8% of necropsies, we surveyed for reactive serum 
antibodies in an enzyme-linked immunosorbent assay (ELISA) 
against a crude saline extract obtained from the epimastigote stage 
of Mexican isolates of T. cruzi, as well as for antibodies reactive 
with epimastigotes in an indirect immunofluorescent assay. The 
presence of antibodies against T. cruzi in sera positive-on both 
tests was confirmed by a Western blot assay. These tests were pre- 
viously validated in our population and by external controls.g 
Thirty-seven patients were studied; all of them had a definite di- 
agnosis of dilated cardiomyopathy of unknown origin and 15 ‘of 
them (40%) had antibodies against 7’. cruzi. There was no differ- 
ence in the clinical picture between patients with or without an- 
ti-T. cruzi antibodies; however, a significant difference was present 
between both groups in regard to rural origin and residence, poor 
housing, and vector recognition (p < 0.01). Our results suggest that 
Chagas’ disease could be a relatively common cause of chronic 
chagasic cardiopathy (CCC). In fact, dilated cardiomyopathy is a 
well-known expression of Chagas’ disease, and these cases are 
considered idiopathic if serologic testing is not performed. Besides 
and perhaps more important, is the fact that mast people infected 
with 2’. cruzi’do not develop CCC or any other clinical feature; they 
are asymptomatic end only the presence of serum-specific anti- 
bodies allows their recognition as so-called “indeterminate” cha- 
gasic individualslo These people may be a source of infection 
through blood or even organ donation for transplantation. A def- 
inite risk for iatrogenic spreading of this deadly condition daes 
exist and the search for anti-T. cruzi antibodies in the blood of or- 
gan donors should be mandatory. Because of the continuing social 
phenomenon of migration to the United States and Canada, this 
disease may be a potential problem in North America that needs 
to be measured accurately. 
Pedro A. Reyes, MD 
National Institute of Cardiology 
Juan Badiano I 
14080 Mexico, D.F. 
Mexico City, Mexico 
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U.S. TRENDS IN RHEUMATK FEVER AND 
HEART DISEASE 
To the Editor: 
Articles and editorials have described the decline in acute rheu- 
matic fever and trends in chronic rheumatic heart disease in the 
United States1 More recently reports have appeared that suggest 
that a resurgence of acute rheumatic fever took place in the mid 
1980s.’ Therefore I examined recent morbidity and mortality sta- 
tistics from the National Center for Health Statistics. In 1988 
through 1990 an estimated 16,792 hospital discharges had any di- 
agnosis of acute rheumatic fever, International Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9 CM) codes 
390 through 392, compared to 18,791 in 1985 through 1987. HOW- 
ever, the number of such cases is too small to permit accurate es- 
